{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:05:17Z","timestamp":1779890717447,"version":"3.53.1"},"reference-count":102,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Despite significant progress in management of acute coronary syndromes (ACSs), they continue to be a major cause of death worldwide due to residual inflammatory risk (RIR). Aim: This study reviews existing clinical evidence for anti-inflammatory therapies in coronary heart disease (CHD) and assesses precision medicine in classifying patients from clinical, immunological, and genetic perspectives. Results: Large clinical trials confirm the inflammatory hypothesis of atherosclerosis. Therapies targeted at the specific NLRP3 inflammasome\/interleukin-1\u03b2 (IL-1\u03b2)\/interleukin-6 (IL-6) pathway reduce major adverse cardiovascular events (MACEs), while broad immunosuppression fails. This highlights the need for molecular specificity. Precision cardiology aims to identify high-risk inflammatory phenotypes through clonal hematopoiesis of indeterminate potential (CHIP). Mutations in genes such as TET2 and ASXL1 lead to macrophage hyperreactivity and increased plaque vulnerability. Available data suggest that the effectiveness of immunomodulatory treatment strongly depends on timing. Starting therapy early with SGLT2 inhibitors (SGLT2is) or agents that target temporarily activated receptors like P2Y11 seems to be essential for managing harmful inflammation while supporting myocardial repair. Conclusions: Precision cardiology aims to integrate targeted anti-inflammatory therapies with established clinical markers, while future pathways may incorporate advanced immunophenotyping and genetic risk assessment as they undergo clinical validation.<\/jats:p>","DOI":"10.3390\/jcm15114143","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:31:56Z","timestamp":1779885116000},"page":"4143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Inflammatory Therapies in Acute Coronary Syndromes\u2014A Review of Immunological, Genetic, and Clinical Challenges for Precision Medicine"],"prefix":"10.3390","volume":"15","author":[{"given":"Mateusz","family":"Dudek","sequence":"first","affiliation":[{"name":"Student Scientific Group of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"G\u00f3rniak","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4777-4024","authenticated-orcid":false,"given":"Aleksandra","family":"Z\u0142otowska","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Gajewski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1161\/CIR.0000000000001412","article-title":"2026 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association","volume":"153","author":"Palaniappan","year":"2026","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pan, W., Zhou, G., Hu, M., Li, G., Zhang, M., Yang, H., Li, K., Li, J., Liu, T., and Wang, Y. (2024). Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3\/IL1\u03b2 pathway. BMC Cardiovasc. Disord., 24.","DOI":"10.1186\/s12872-024-03729-x"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-Target or High-Intensity Statin in Patients with Coronary Artery Disease: A Randomized Clinical Trial","volume":"329","author":"Hong","year":"2023","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacasi.2021.12.003","article-title":"Residual Inflammatory Risk After Percutaneous Coronary Intervention: Underappreciated But Modifiable","volume":"2","author":"Henriques","year":"2022","journal-title":"JACC Asia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: A CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/eurheartj\/ehw207","article-title":"Anti-inflammatory treatment of acute coronary syndromes: The need for precision medicine","volume":"37","author":"Crea","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5551\/jat.RV17001","article-title":"Role of NLRP3 Inflammasomes in Atherosclerosis","volume":"24","author":"Karasawa","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/jcp.25930","article-title":"NLRP3 inflammasome: Its regulation and involvement in atherosclerosis","volume":"233","author":"Hoseini","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Association of Interleukin 6 Inhibition with Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/dc23-1825","article-title":"Low-Dose Colchicine in Patients with Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"47","author":"Roubille","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"82","author":"Wada","year":"2023","journal-title":"J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/eurheartj\/ehaf289","article-title":"Acute coronary syndromes: Mechanisms, challenges, and new opportunities","volume":"46","author":"Kraler","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jacc.2014.11.041","article-title":"The Myth of the \u201cVulnerable Plaque\u201d: Transitioning from a Focus on Individual Lesions to Atherosclerotic Disease Burden for Coronary Artery Disease Risk Assessment","volume":"65","author":"Fuster","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4904217","DOI":"10.1155\/2020\/4904217","article-title":"Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications","volume":"2020","author":"Wang","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute coronary syndromes: The way forward from mechanisms to precision treatment","volume":"136","author":"Crea","year":"2017","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/14728222.2020.1795831","article-title":"Inflammasomes: A preclinical assessment of targeting in atherosclerosis","volume":"24","author":"Stitham","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41598-024-85041-4","article-title":"The effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome","volume":"15","author":"Mo","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kelley, N., Jeltema, D., Duan, Y., and He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133328"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Xue, C., Chen, Q., Bian, L., Yin, Z., Xu, Z., Zhang, H., Zhang, Q., Zhang, J., Wang, C., and Du, R. (2022). The relationships between cholesterol crystals, NLRP3 inflammasome, and coronary atherosclerotic plaque vulnerability in acute coronary syndrome: An optical coherence tomography study. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.905363"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102985","DOI":"10.1016\/j.ebiom.2020.102985","article-title":"Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis","volume":"60","author":"Niyonzima","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2562267","DOI":"10.1080\/09537104.2025.2562267","article-title":"The NLRP3 inflammasome in platelets\u2013form, functions, and future of the complex","volume":"36","author":"Hindle","year":"2025","journal-title":"Platelets"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cca.2020.06.044","article-title":"Pyroptosis: A pro-inflammatory type of cell death in cardiovascular disease","volume":"510","author":"Wang","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"uxae117","DOI":"10.1093\/cei\/uxae117","article-title":"FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases","volume":"219","author":"Topping","year":"2025","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"H265","DOI":"10.1152\/ajpheart.00509.2016","article-title":"L5-LDL from ST-elevation myocardial infarction patients induces IL-1 production via LOX-1 and NLRP3 inflammasome activation in macrophages","volume":"312","author":"Yang","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e24229","DOI":"10.1002\/clc.24229","article-title":"Prognostic significance of IL-18 in acute coronary syndrome patients","volume":"47","author":"Xiong","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/clc.23274","article-title":"Interleukin-18 in patients with acute coronary syndromes","volume":"42","author":"James","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kaura, A., Hartley, A., Panoulas, V., Glampson, B., Shah, A.S.V., Davies, J., Mulla, A., Woods, K., Omigie, J., and Shah, A.D. (2022). Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003911"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Trimarchi, G., Pizzino, F., Lilli, A., De Caterina, A.R., Esposito, A., Dalmiani, S., Mazzone, A., Di Bella, G., Berti, S., and Paradossi, U. (2024). Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206059"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.14744\/AnatolJCardiol.2024.4001","article-title":"The Role of Pyroptosis in Coronary Heart Disease","volume":"28","author":"Qiu","year":"2024","journal-title":"Anatol. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2917128","DOI":"10.1155\/2019\/2917128","article-title":"IFN regulatory factor 1 mediates macrophage pyroptosis induced by oxidized low-density lipoprotein in patients with acute coronary syndrome","volume":"2019","author":"Guo","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/heartjnl-2024-325408","article-title":"Inflammation in coronary atherosclerosis: Diagnosis and treatment","volume":"111","author":"Occhipinti","year":"2025","journal-title":"Heart"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jacc.2019.07.061","article-title":"From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week","volume":"74","author":"Libby","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/jtd.2018.01.119","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease: Lessons from the CANTOS trial","volume":"10","author":"Thompson","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ahj.2024.09.006","article-title":"Exploration of the regional effects of colchicine in the LoDoCo2 trial","volume":"278","author":"Budgeon","year":"2024","journal-title":"Am. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e038687","DOI":"10.1161\/JAHA.124.038687","article-title":"Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial","volume":"14","author":"Mohammadnia","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/eurheartj\/ehae208","article-title":"Low-dose colchicine for atherosclerosis: Long-term safety","volume":"45","author":"Nidorf","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","article-title":"Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management","volume":"46","author":"Hansten","year":"2023","journal-title":"Drug Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-025-03815-9","article-title":"The effect of colchicine on coagulation in patients with chronic coronary disease who use vitamin K antagonists","volume":"81","author":"Houwen","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/eurheartj\/ehad453","article-title":"Colchicine for cardiovascular prevention: The dawn of a new era has finally come","volume":"44","author":"Bonaventura","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week","volume":"82","author":"Nelson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","first-page":"e29518","article-title":"Overview of Methotrexate Toxicity: A Comprehensive Literature Review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.14740\/jmc5159","article-title":"A Clinical Case of Methotrexate Toxicity","volume":"16","author":"Peixoto","year":"2025","journal-title":"J. Med. Cases"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/rheumatology\/keaa650","article-title":"Adverse effects related to methotrexate polyglutamate levels: Adjudicated results from the cardiovascular inflammation reduction trial","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fca-2021-0027","article-title":"Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2)","volume":"17","author":"Samuel","year":"2021","journal-title":"Future Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated with Combination Lipid-Lowering and Inflammation-Inhibiting Agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","article-title":"The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina","volume":"331","author":"Liuzzo","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1093\/eurheartj\/eht435","article-title":"How to use C-reactive protein in acute coronary care","volume":"34","author":"Biasucci","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","article-title":"Low-Dose Colchicine and High-Sensitivity C-Reactive Protein after Myocardial Infarction: A Combined Analysis Using Individual Patient Data from the COLCOT and LoDoCo-MI Studies","volume":"363","author":"Sun","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"7","author":"Samuel","year":"2021","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e003183","DOI":"10.1161\/CIRCGEN.120.003183","article-title":"Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT","volume":"14","author":"Legault","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.124.069808","article-title":"Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial","volume":"150","author":"Yu","year":"2024","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2023.01.030","article-title":"Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence Tomography","volume":"81","author":"Jiang","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2020.08.009","article-title":"Macrophage infiltrates in coronary plaque erosion and cardiovascular outcome in patients with acute coronary syndrome","volume":"311","author":"Montone","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.jacadv.2025.101622","article-title":"Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States","volume":"4","author":"Buckley","year":"2025","journal-title":"JACC Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2431309","DOI":"10.1001\/jamanetworkopen.2024.31309","article-title":"Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients with COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial","volume":"7","author":"Alfehaid","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zhang, S., Yan, M.-M., Zhao, H., Qiu, X.-Y., and Zhu, D. (2024). Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: Identifying the likelihood of drug\u2013drug interactions through the FDA adverse event reporting system. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1445324"},{"key":"ref_73","first-page":"e95715","article-title":"Low-Dose Colchicine in Patients with Type 2 Diabetes with Recent Myocardial Infarction in the Colchicine Cardiovascular Outcome Trial (COLCOT): A Systematic Review","volume":"17","author":"Shoaib","year":"2025","journal-title":"Cureus"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/ATVBAHA.125.322533","article-title":"Direct Interleukin-6 Inhibition Blunts Arterial Thrombosis by Reducing Collagen-Mediated Platelet Activation","volume":"45","author":"Ministrini","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s44161-025-00700-7","article-title":"IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk","volume":"4","author":"Zhang","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101319","DOI":"10.1016\/j.jacbts.2025.101319","article-title":"C-Reactive Protein as a Potential Signpost to Trained Immunity","volume":"10","author":"Choudhury","year":"2025","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1136\/annrheumdis-2023-eular.600","article-title":"AB1247 Rationale and Design for PODAGRA II: A Multicenter Randomized Phase 2\/3 Study Assessing the Efficacy and Safety of Dapansutrile, an Orally Administered Specific Inhibitor of the NLRP3 Inflammasome in Subjects with an Acute Gout Flare","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Pathangey, G., Allam, M.N., Abdelnabi, M.H., Sorajja, D., Fortuin, F.D., Lee, K.S., and Bhakta, M.D. (2025). Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes. J. Clin. Med., 14.","DOI":"10.3390\/jcm14227910"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"120443","DOI":"10.1016\/j.atherosclerosis.2025.120443","article-title":"Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients","volume":"408","author":"Tardif","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"(2012). The Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N. Engl. J. Med., 367, 1310\u20131320.","DOI":"10.1056\/NEJMoa1107477"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1186\/s13073-025-01531-8","article-title":"Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction","volume":"17","author":"Li","year":"2025","journal-title":"Genome Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Opstad, T.B., Solheim, S., Pettersen, A.\u00c5.R., Kalstad, A.A., Arnesen, H., and Seljeflot, I. (2022). TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patients-A Possible Link to Clonal Hematopoiesis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082027"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12933-025-03042-7","article-title":"Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes","volume":"25","author":"Cliff","year":"2026","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after Acute Myocardial Infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized Trial of Empagliflozin in Nondiabetic Patients with Heart Failure and Reduced Ejection Fraction","volume":"77","author":"Mancini","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"He, D., Li, Y., Jiang, Z., Cao, X., and Luo, R. (2025). Efficacy of new immunomodulatory drugs on major adverse cardiovascular events in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 25.","DOI":"10.1186\/s12872-025-05250-1"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"477","DOI":"10.23736\/S2724-5683.23.06390-1","article-title":"IL-1 blockade in cardiovascular disease: An appraisal of the evidence across different inflammatory paradigms","volume":"72","author":"Bonaventura","year":"2024","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ihj.2022.11.001","article-title":"Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction","volume":"74","author":"Basia","year":"2022","journal-title":"Indian Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ihj.2022.11.014","article-title":"Novel lipid biomarkers and associated gene polymorphism in young ST-segment elevation myocardial infarction","volume":"75","author":"Muheeb","year":"2023","journal-title":"Indian Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Luo, Y., Li, S., Ding, Y., and Shi, S. (2025). Association of IL-10, IL-6, and TNF-\u03b1 polymorphisms with acute coronary syndrome risk: A systematic review, meta-analysis, and trial sequential analysis. BMC Med. Genom., 18.","DOI":"10.1186\/s12920-025-02167-8"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1186\/s12933-025-02777-7","article-title":"Impact of sodium\u2013glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: A comprehensive review","volume":"24","author":"Yoo","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e70059","DOI":"10.1111\/dme.70059","article-title":"The cardio-renal-metabolic role of the nod-like receptor protein-3 and senescence-associated secretory phenotype in early sodium\/glucose cotransporter-2 inhibitor therapy in people with diabetes who have had a myocardial infarction","volume":"42","author":"Shah","year":"2025","journal-title":"Diabet. Med."},{"key":"ref_97","first-page":"17532","article-title":"Human peripheral blood mononuclear cells display a temporal evolving inflammatory profile after myocardial infarction and modify myocardial fibroblasts phenotype","volume":"13","author":"Monnier","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Brie, D.M., Morno\u0219, C., Adam, O., T\u00eerziu, A., Popescu, R., and Brie, A.D. (2025). Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets. Cells, 15.","DOI":"10.3390\/cells15010072"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e113279","DOI":"10.15252\/embj.2022113279","article-title":"Systematic P2Y receptor survey identifies P2Y11 as modulator of immune responses and virus replication in macrophages","volume":"42","author":"Andersen","year":"2023","journal-title":"EMBO J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Medina-Leyte, D.J., Zepeda-Garc\u00eda, O., Dom\u00ednguez-P\u00e9rez, M., Gonz\u00e1lez-Garrido, A., Villarreal-Molina, T., and Jacobo-Albavera, L. (2021). Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083850"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40256-025-00739-8","article-title":"One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry","volume":"25","author":"Spadafora","year":"2025","journal-title":"Am. J. Cardiovasc. Drugs"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:20:32Z","timestamp":1779888032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":102,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114143"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114143","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}